Summa is a National Site for the Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
Acute ischemic stroke is a major cause of disability in adults, frequently requiring significant long term care. A large proportion of patients are hyperglycemic when they arrive at the hospital (40 percent), and being hyperglycemic is associated with worse outcomes. It is not known, however, if tight glucose control during the time period following stroke would improve outcomes. Additionally, severe or prolonged hypoglycemia can also be damaging to the ischemic brain.
The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial is a multicenter, randomized, Phase III clinical trial of 1,400 patients who will be randomized to receive either intravenous insulin with tight glucose control or standard sliding scale subcutaneous insulin. Patients will be enrolled to the study within 12 hours of the onset of symptoms. Clinical outcomes at three months will be compared in the two groups. Summa Health System is one of approximately 60 national sites for this study and is collaborating with the Ohio State University Wexner Medical Center on this effort. Susana Bowling, M.D. is the Summa study site Principal Investigator. More information on this clinical trial is available here.